New FDA-Approved BEQALZI Cancer Pill For Mantle Cell Lymphoma. Watch oncologist from MD Anderson Hospital in Houston Texas.

In this episode

New FDA-Accelerated approval for BEQALZI pill to treat Mantle Cell Lymphoma cancers that are resistant to or recur with older treatments. Watch video podcast with expert, Michael Wang, M.D. , who explains the disease and BEQALZI made by BeOne Medicines.DoctorPodcasts EPISODE 170 Timeline/ Chapters: - Introduction & Welcome - Meet Dr. Michael Wang (MD Anderson Cancer Center) - What Is Lymphoma? (Liquid Cancers vs. Solid Tumors) - What Makes Mantle Cell Lymphoma Unique & Difficult to Treat? - Who Gets Mantle Cell Lymphoma? (Demographics & Risk Factors) - Symptoms of Mantle Cell Lymphoma - How MCL Is Diagnosed: Biopsies, Markers & Flow Cytometry - The Evolution of Treatment: Moving Beyond Chemotherapy - Targeted Therapies: BTK Inhibitors & CAR T-Cell Therapy - Understanding BCL-2 Inhibitors in Cancer Mitochondria - BEQALZI (Sonrotoclax): Breakthrough BCL-2 Inhibitor - What Is FDA Accelerated Approval? - BEQALZI Clinical Trial Results & Response Rates - Dosing & Treatment Duration (Once-Daily Pill) - Availability & Sonrotoclax vs. Venetoclax - BeOne Medicines & Global Collaboration - Conclusion & Closing Remarks